Item 16. Form 10-K Summary.

Not applicable.

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


ALIGN TECHNOLOGY, INC.

By:			/S/ JOSEPH M. HOGAN
			Joseph M. Hogan
			President and Chief Executive Officer
Date:			February 25, 2022

Each person whose signature appears below constitutes and appoints Joseph M. Hogan or John F. Morici, his or her attorney-in-fact, with the power of substitution, for him or her in any and all capacities, to sign any amendments to this Report on Form 10-K and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, hereby ratifying and confirming all that each of said attorneys-in-fact, or his or her substitute or substitutes, may do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.


Signature	Title	Date

/S/ JOSEPH M. HOGAN	President and Chief Executive Officer (Principal Executive Officer)	February 25, 2022
Joseph M. Hogan

/S/ JOHN F. MORICI	Chief Financial Officer and Executive Vice President, Global Finance (Principal Financial Officer and Principal Accounting Officer)	February 25, 2022
John F. Morici

/S/ KEVIN J. DALLAS	Director	February 25, 2022
Kevin J. Dallas

/S/ JOSEPH LACOB	Director	February 25, 2022
Joseph Lacob

/S/ C. RAYMOND LARKIN, JR.	Director	February 25, 2022
C. Raymond Larkin, Jr.

/S/ GEORGE J. MORROW	Director	February 25, 2022
George J. Morrow

/S/ ANNE M. MYONG	Director	February 25, 2022
Anne M. Myong

/S/ ANDREA L. SAIA	Director	February 25, 2022
Andrea L. Saia

/S/ GREG J. SANTORA	Director	February 25, 2022
Greg J. Santora

/S/ SUSAN E. SIEGEL	Director	February 25, 2022
Susan E. Siegel

/S/ WARREN S. THALER	Director	February 25, 2022
Warren S. Thaler

Previous: Item 15. Exhibit and Financial Statement Schedules.